Crestor vs Leqvio: Switching Between Rosuvastatin and Inclisiran

How Rosuvastatin and Inclisiran Lower LDL-C Through Different Pathways

Rosuvastatin blocks HMG-CoA reductase, the enzyme that drives cholesterol synthesis in the liver. Inclisiran silences the gene that produces PCSK9, a protein responsible for degrading LDL receptors on liver cells. Both approaches increase the number of LDL receptors clearing cholesterol from the bloodstream, but they do so at completely different biological steps.

Rosuvastatin acts within minutes of hepatic uptake, competitively inhibiting the rate-limiting step in the mevalonate pathway. This triggers an upregulation of LDL receptor expression on hepatocyte surfaces as the liver compensates for reduced intracellular cholesterol production. The result: circulating LDL particles are pulled from the blood more aggressively. At the 40 mg dose, rosuvastatin produces mean LDL-C reductions of 52.4% according to prescribing data from the FDA.

Inclisiran takes a completely different route. It is a synthetic double-stranded siRNA conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs it specifically to hepatocytes. Once inside the cell, inclisiran degrades PCSK9 messenger RNA before the protein can be translated. Fewer PCSK9 proteins means fewer LDL receptors get tagged for destruction. The net effect mirrors monoclonal antibody PCSK9 inhibitors like evolocumab, but the siRNA mechanism provides durable suppression lasting approximately six months per dose. In ORION-10 and ORION-11 (N=3,178 combined), inclisiran reduced LDL-C by 52.3% and 49.9%, respectively, at day 510 [1].

Because these two drugs target separate nodes in the same LDL-clearance cascade, their effects can be additive. A patient already on rosuvastatin 20 mg who adds inclisiran could see LDL-C drop from, say, 95 mg/dL to the low 40s. That stacking principle is central to understanding why clinicians often combine them rather than swap one for the other.

Head-to-Head Efficacy: What the Trial Data Actually Shows

No randomized controlled trial has directly compared rosuvastatin against inclisiran as monotherapies. The clinical evidence comes from separate key programs with different patient populations, so any comparison requires careful cross-trial interpretation.

The JUPITER trial (N=17,802) randomized apparently healthy men and women with LDL-C <130 mg/dL but high-sensitivity C-reactive protein (hsCRP) ≥2.0 mg/L to rosuvastatin 20 mg or placebo [2]. Over a median follow-up of 1.9 years (trial stopped early for efficacy), rosuvastatin reduced the primary composite endpoint of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or confirmed cardiovascular death by 44% (HR 0.56 to 95% CI 0.46-0.69, P<0.00001). LDL-C dropped 50% and hsCRP fell 37%.

The ORION trials enrolled a different population. ORION-10 enrolled patients with atherosclerotic cardiovascular disease (ASCVD) and ORION-11 enrolled patients with ASCVD or ASCVD risk equivalents, all with elevated LDL-C despite maximally tolerated statin therapy [1]. The ~50% LDL-C reduction demonstrated by inclisiran was achieved on top of background statin use, not instead of it. Roughly 89% of ORION-11 participants and 69% of ORION-10 participants were already taking a statin at baseline.

This distinction matters. Inclisiran's 50% reduction is additive. Rosuvastatin's 50% reduction is from an untreated baseline. The two numbers are not interchangeable.

Dr. Kausik Ray, lead investigator of the ORION program and Professor of Public Health at Imperial College London, stated in the ORION-11 publication: "Inclisiran, administered as a subcutaneous injection every 6 months, produced durable reductions in LDL cholesterol levels that were sustained over the 540-day trial period" [1].

The 2022 ACC Expert Consensus Decision Pathway recommends maximizing statin therapy before considering PCSK9-targeted agents, positioning inclisiran as second-line or add-on rather than a first-choice replacement for statins.

When Clinicians Consider Switching From Crestor to Leqvio

The most common clinical scenario prompting a switch is statin intolerance. Between 5% and 20% of statin users report muscle-related symptoms, and while true statin-associated muscle symptoms (SAMS) confirmed by rechallenge affect a smaller fraction, the clinical reality is that many patients discontinue therapy. For those patients, inclisiran offers an alternative LDL-lowering mechanism without exposure to the mevalonate pathway inhibition responsible for myotoxicity.

A second scenario involves patients who have maxed out statin therapy and still fall short of their LDL-C target. The 2018 AHA/ACC Cholesterol Guidelines define high-risk thresholds where LDL-C <70 mg/dL (or even <55 mg/dL in very high-risk groups per ESC/EAS guidelines) is the goal [3]. A patient on rosuvastatin 40 mg with ezetimibe who still sits at 85 mg/dL may need a PCSK9-targeted therapy to close that gap.

Third, adherence failure drives switches. Statins require daily dosing, and real-world adherence data is poor. A 2019 meta-analysis in the European Heart Journal found that only about 50% of patients remained adherent to statins at 1 year [4]. Inclisiran's twice-yearly injection, administered in a healthcare setting, removes the daily compliance burden entirely. The patient cannot forget a dose they receive in a clinic.

Not every switch is a full replacement. Many patients are transitioned to a reduced statin dose plus inclisiran. A patient experiencing myalgia on rosuvastatin 40 mg might step down to rosuvastatin 5 mg (which alone produces roughly 38-40% LDL-C reduction) and add inclisiran to cover the remaining gap.

How to Switch: The Clinical Protocol

Switching between Crestor and Leqvio is not a self-directed process. It requires baseline labs, risk stratification, and a clear therapeutic rationale.

The standard workflow begins with a fasting lipid panel and documentation of the reason for the switch: intolerance (with symptom details), inadequate response (with LDL-C values on current therapy), or adherence concerns. If statin intolerance is the driver, the National Lipid Association recommends a structured statin rechallenge using a different statin or reduced dosing frequency before abandoning the class entirely [5].

For patients transitioning to inclisiran, the dosing schedule is fixed: 284 mg subcutaneously at day 0, day 90, and every 6 months thereafter. The first injection can be given at the same visit where the statin is discontinued or reduced. However, because inclisiran takes approximately 30-90 days to reach maximal LDL-C lowering, clinicians should anticipate a temporary LDL-C rebound during the transition window if the statin is stopped abruptly.

A practical approach used by lipid specialists is the "bridge and check" method:

1. Administer the first inclisiran injection while maintaining the current statin dose.
2. Recheck LDL-C at 8-12 weeks (around the second injection).
3. If LDL-C is at goal, consider reducing or stopping the statin at that point.
4. Recheck again at 6 months to confirm sustained control.

This phased transition avoids the LDL-C gap that could leave a high-risk patient unprotected during the inclisiran ramp-up period. For patients with recent acute coronary syndrome or LDL-C >190 mg/dL, most guidelines suggest maintaining at least a low-dose statin alongside inclisiran given the pleiotropic anti-inflammatory benefits statins provide beyond LDL lowering, including the hsCRP reductions demonstrated in JUPITER.

Cost and Insurance: The Practical Barrier to Switching

The cost difference between these two drugs is significant. Generic rosuvastatin is available for as little as $10-30 per month at most pharmacies, placing it among the most affordable cardiovascular medications in existence. Leqvio carries a wholesale acquisition cost of approximately $6,500 per injection, or roughly $13,000 per year before insurance adjustments.

Most commercial insurers and Medicare Part D plans impose prior authorization requirements for inclisiran, typically requiring documentation of statin intolerance or failure to reach LDL-C goals on maximally tolerated therapy. The FDA approval label specifies inclisiran for adults with ASCVD or heterozygous familial hypercholesterolemia (HeFH) who require additional LDL-C lowering [6].

Novartis, Leqvio's manufacturer, offers patient assistance programs that can reduce out-of-pocket costs to as low as $0 for commercially insured patients. Medicare patients face more complex coverage dynamics, as Part B (if the injection is administered in a physician's office) and Part D (if dispensed as a pharmacy benefit) handle the drug differently. The Centers for Medicare and Medicaid Services (CMS) has issued guidance classifying inclisiran as a Part D drug in most scenarios.

For self-pay patients, the cost-effectiveness calculation depends entirely on cardiovascular risk. A patient with familial hypercholesterolemia and an LDL-C of 190 mg/dL despite maximal statin therapy faces a different value proposition than someone with borderline-elevated LDL and no ASCVD history.

Safety Profiles Compared

Rosuvastatin's safety profile has been characterized across more than two decades and tens of millions of patient-years. The primary concerns are myopathy (including rare rhabdomyolysis at an estimated incidence of 0.1-0.4 per 10,000 patient-years), hepatotoxicity (transaminase elevations >3x ULN occur in <1% of patients), and a modest increase in new-onset type 2 diabetes [7]. The JUPITER trial found a 25% increase in physician-reported diabetes in the rosuvastatin group (HR 1.25, P=0.01), an effect now recognized as a statin class effect that is dose-dependent [2].

Inclisiran's safety data, while encouraging, covers a shorter observation window. Across ORION-9, -10, and -11, the most common adverse event was injection-site reaction, occurring in 5% of inclisiran-treated patients versus 0.7% on placebo. These reactions were predominantly mild (erythema, pain, rash) and did not lead to treatment discontinuation. Nasopharyngitis, urinary tract infection, and back pain occurred at rates similar to placebo. No clinically significant hepatotoxicity or myopathy signals emerged [1].

One theoretical concern with all PCSK9-lowering therapies is achieving very low LDL-C levels (<25 mg/dL). Long-term outcome studies with evolocumab (FOURIER) have not identified safety signals at these levels over 2-3 years, but data beyond 5 years remain limited. The ongoing ORION-4 cardiovascular outcomes trial (N~15,000) will provide the first dedicated MACE endpoint data for inclisiran, with results anticipated in late 2026 [8].

Neither drug is recommended during pregnancy. Rosuvastatin is classified as contraindicated. Inclisiran lacks adequate human pregnancy data, and the prescribing information advises against use in pregnant women.

Combination Therapy: Why "Or" Is Often the Wrong Question

The framing of Crestor "versus" Leqvio misrepresents how these drugs are used in practice. For the majority of patients prescribed inclisiran, the goal is not replacement but augmentation.

The European Society of Cardiology (ESC) 2019 dyslipidemia guidelines recommend a stepwise approach: maximize statin dose first, add ezetimibe second, and add a PCSK9-targeting therapy third [9]. This tiered algorithm means that most inclisiran candidates are already on a statin. Removing the statin entirely would sacrifice a 45-55% LDL reduction that inclisiran alone may not fully replicate when used as monotherapy.

Data from ORION-9 (patients with HeFH) illustrate this point [10]. In that trial, patients on maximally tolerated lipid-lowering therapy (primarily statins) who added inclisiran achieved a 39.7% additional LDL-C reduction beyond what their background regimen accomplished. If those patients had stopped their statin, their net LDL-C would have been higher than on statin alone.

The exception is the genuinely statin-intolerant patient who cannot tolerate any statin at any dose. For that population, inclisiran as monotherapy (sometimes combined with ezetimibe and/or bempedoic acid) represents a viable primary LDL-lowering strategy. Registry data suggest this truly intolerant group represents approximately 3-5% of patients who attempt statin therapy.

The Missing Piece: Cardiovascular Outcomes for Inclisiran

Rosuvastatin has confirmed MACE reduction. That is a critical distinction. JUPITER showed a 44% reduction in major cardiovascular events, and the broader statin evidence base (CTT Collaboration meta-analysis of 26 trials, N=170,000+) confirms that each 1 mmol/L (38.7 mg/dL) reduction in LDL-C via statins produces a 22% proportional reduction in major vascular events [11].

Inclisiran does not yet have this evidence. The ORION program used LDL-C reduction as a surrogate endpoint, which is accepted by the FDA for drug approval. But surrogate endpoints and hard outcomes are not the same thing. The PCSK9 monoclonal antibodies (evolocumab and alirocumab) have bridged this gap with positive CVOT results in FOURIER and ODYSSEY OUTCOMES, and the mechanism of LDL-C lowering via PCSK9 inhibition is biologically consistent. Most lipid experts consider it highly probable that inclisiran will show MACE reduction in ORION-4. Probable is not proven.

This distinction should influence switching decisions. A patient doing well on rosuvastatin with no side effects and LDL-C at goal has no clinical reason to switch to inclisiran. The switch conversation becomes relevant only when the statin is insufficient or intolerable.

Rosuvastatin 20 mg remains the starting point for adults with LDL-C >190 mg/dL or 10-year ASCVD risk ≥7.5%, per USPSTF 2022 statin recommendations [12]. Inclisiran enters the algorithm when that foundation proves inadequate.